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Farnesyl transferase inhibitors: the successes and surprises 
of a new class of potential cancer chemotherapeutics 
Proteins that transmit abnormal growth signals offer enticing points of intervention for 
the treatment of cancer. The discovery that isoprenoid attachment is required for the 
aberrant biological activity of oncogenic Ras proteins has provided just such a target. 
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For more than two decades the family of Ras proteins 
has been under intense study because of their central 
role in cell growth and their intimate association with 
an estimated 30 % of all human cancers [l]. Ras proteins 
must be localized to the plasma membrane in order to 
transform cells, and covalently attached lipids are the 
major impetus for this membrane interaction (Fig. 1) 
[2]. This discovery has led to the idea that preventing 
attachment of these lipids might disrupt the aberrant 
growth signals of oncogenic Ras proteins [3] and has 
propelled development of the first drugs designed to 
inhibit a lipid transferase. Several such compounds are 
now ready for rigorous testing in animal models of 
tumor growth. 
Four central questions need to be answered before such 
inhibitors become useful. Will the inhibition of lipid 
transfer completely or partially eliminate the activity of 
oncogenic Ras? If the normal route of lipid transfer to 
Ras is blocked, can other mechanisms be used to activate 
Ras instead? Can other protein(s) or signaling pathways 
unaffected by inhibition of lipid transfer function as a 
surrogate for Ras? And, finally, will the activity of other 
proteins that share the same lipid transfer pathway as Ras 
be compromised and lead to unmanageable toxicity? 
A primer on protein prenylation 
Isoprenoids have been found only on three classes of 
proteins, defined by the presence of specific carboxy- 
terminal signals for three distinct prenyl transferase 
enzymes. Two classes of prenylated proteins have what 
are called CaaX motifs, composed of a cysteine followed 
by two (usually but not always) aliphatic residues and a 
carboxy-terminal ‘X’ residue. The amino acid in the ‘X’ 
position is important in determining which prenyl 
transferase will recognize the protein substrate [2]. 
Proteins with X = Leu (CaaL) are recognized by geran- 
ylgeranyl transferase I (GGTase I) and modified with the 
C,, isoprenoid geranylgeranyl. CaaL proteins are much 
more numerous than those in the other CaaX class, in 
which the X is Met, Ser,Ala, or Gln. Ras proteins are in 
this latter group, and are modified with a C,, isoprenoid 
by a farnesyl transferase (FTase). In general, proteins iso- 
lated from cells are modified by a single size of iso- 
prenoid, rather than a mixture of C,, and C,, lipids (but 
see two important exceptions below). It is not yet 
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Fig 1. Ras and Ras farnesylation in cell 
proliferation. The binding of a growth 
factor to a receptor tyrosine kinase leads 
to conversion of inactive Ras (GDP) to 
active Ras (GTP). The protein kinase Raf 
then interacts with the GTP form of Ras 
and is thus recruited to the membrane. 
The now active Raf initiates a phospho- 
rylation cascade that transmits a prolifer- 
ative signal to the nucleus. The activity of 
Ras is dependent on its membrane local- 
ization, which is in turn dependent on 
the attachment of a C, s farnesyl group by 
FTase to the CaaX motif (where a is an 
aliphatic residue and X is Met, Ser, Ala or 
Gin) at the carboxyl terminus of Ras. 
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known whether inhibitors of FTase can cause some pro- 
teins that are normally modified with C,, lipid to 
switch to C,, modification. The third class of prenylated 
proteins have a carboxy-terminal Cys-X-Cys or X-Cys- 
Cys motif and are modified by a distinct geranylgeranyl 
transferase, GGTase II. Current FTase inhibitors cause 
no detectable changes in the prenylation of this third 
class of proteins. 
Design of farnesyl transferase inhibitors 
Routes to inhibitors of Ras farnesylation are apparent 
from an examination of the substrate specificities of the 
enzyme. One can design analogs either of the lipid, or of 
the peptide sequence to which the lipid is transferred. 
Such compounds must be stable, and readily cross the 
cell membrane to gain access to the cytosolic transferase. 
Two examples of farnesyl diphosphate analogs are shown 
in Table 1. Both a-hydroxyfarnesyl phosphonic acid [4] 
(HFP) and a B-carboxy phosphonic acid derivative [5] 
(FCP) are potent inhibitors of FTase, showing >lOOO-fold 
selectivity over GGTase I or squalene synthetase in vitro. 
Esterification of the carboxylate group of FCP improves 
cell penetration. The FCP prodrug inhibits the growth of 
H-Ras-transformed NIH 3T3 cells at 100 PM, but also 
inhibits protein geranylgeranylation [5]. 
Non-substrate peptide inhibitors based on the CaaM 
motif, which is recognized preferentially by FTase, 
prove more potent and selective than the lipid analogs. 
Modification of the backbone of the CaaM tetrapep- 
tide with reduced amide, olefin, or ether linkages gives 
inhibitors (such as B581 and L-739,750; see Table 1) 
that are less readily degraded in viva than the original 
peptide [6,7]. Synthesis of a prodrug of L-739,750 in 
which the terminal carboxylate is masked by esterifica- 
tion gives a compound that inhibits Ras farnesylation 
and membrane binding in cells at low concentrations 
(0.1-l PM) [S]. Such compounds also reduce colony 
formation of H-Ras-transformed cells in soft agar at 1 
PM and block growth of H-Ras tumor xenografts in 
nude mice [9]. The growth obstruction of these com- 
pounds appears to result from inhibition of the Ras 
pathway, as the growth of cells transformed by Raf or 
mos, proteins which function downstream of Ras, is 
not affected. 
The small tetrapeptide recognition sequence of FTase 
provides a guide from which small peptidomimetics can 
be produced. Replacement of the two central hydro- 
phobic residues of the CaaX motif with aminobenzoic 
acid [lo] or aminobenzodiazepine scaffolds [l l] yields 
inhibitors with nanomolar affinity and >50-fold speci- 
ficity for FTase (for example, FTI-276 and BZA-2B; see 
Table 1). An ester prodrug of BZA-2B slows the growth 
of H-Ras-transformed cells, and the ester prodrug of 
FTI-276 completely blocks farnesylation of H-Ras in 
transformed NIH 3T3 cells at 1 pM, and reduces the 
growth of Ras tumors in nude mice at a dose of 
50 mg kg-’ per day [12] (see below). Future peptido- 
mimetic design efforts will benefit from recent NMR 
spectroscopy data showing that the FTase-bound confor- 
mation of the peptide CVWM most closely resembles a 
type III B-turn (Fig. 2) [13]. A completely non-peptidic, 
tricyclic inhibitor (SCH 44342) [14], and bisubstrate 
inhibitors in which an active site model is used as a 
design template and an acyl-phosphinic acid used to link 
farnesol and the tripeptide,Val-Val-Met (BMS 185878) 
[15], have shown impressive effectiveness in intact cells. 
The surprising successes of FTase inhibitors 
The incentive to pursue these inhibitors has grown 
stronger with recent reports that tumors in whole 
animals respond dramatically to inhibitor treatment. 
The prodrugs of L-739,750 and FTI-276 have both 
been shown to block the establishment or slow the 
growth of tumors derived from H-Ras-transformed 
cells transplanted into nude mice [9,12]. The prodrugs 
fail to affect tumor cells that are transformed with Raf, 
the protein immediately downstream of Ras in the 
receptor tyrosine kinase signaling pathway, demonstrat- 
ing that the effects are due to inhibition of Ras farne- 
sylation. These inhibitors were similarly successful in 
preventing tumor growth in nude mice using malig- 
nant human lung cells [12] or human pancreatic ade- 
nocarcinoma cells [9] harboring mutations in the myc 
or ~53 genes in addition to K-Ras. The propyl ester of 
L-739,750 has also been shown to perform exceed- 
ingly well in reducing established mammary and sali- 
vary tumors in transgenic mice that overexpress the 
v-H-Ras oncogene [16], causing complete regression 
of 100 % of small tumors (seven of seven) and partial 
regression in 60 % of large tumors (three of five) when 
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Table 1. Inhibitors of farnesyltransferase. 
Structure Compound IC,,, (nM) 
FTase GGTase 
ref. 
0 
P. 
I OH 
OH 
FCP 83 26,000 [51 
HFP 30 35,800 [41 
S’CH, 
H2N 
SCH, 
8581 21 790 [61 
L739,750 1.8 3,000 PI 
FTI-276 
BZA-2B 
0.5 
0.8 35 1111 
SCH44342 280 >12,000 u41 
kH, 
50 [I 91 
BMS-185878 6 21 1151 
administered to the mice at 40 mg kg-l per day (Fig. The tumor regression seen in these studies is particu- 
3).This response rate was comparable to that produced larly interesting because these compounds had been 
by a more traditional chemotherapeutic, doxyrubicin shown to be anti-proliferative, yet not overtly cytotoxic 
(7 of 11 small tumors treated with the maximum toler- in cell culture. A strong cytostatic effect upon tumor 
ated dose of doxyrubicin showed a detectable decrease cells could be enhanced by a depletion of angiogenic 
in growth, and two regressed completely) [16]. factors required to fully support tumor growth in t&o. 
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Fig. 3. Treatment of v-H-Ras-induced tumors with the peptido- 
mimetic FTase inhibitor, L-744,832 (the propyl ester of L-739,750) 
leads to regression. (a) A mammary adenocarcinoma is clearly 
visible, despite 9 days of treatment with doxyrubicin. (b) After 
treatment of the same mouse with 40 mg kg1 per day of 
L-744,832 for 27 days the tumor has regressed. Reprinted with 
permission from 1161. 
A recent report has shown that FTase inhibition causes 
a 50-90 % reduction in production of the angiogenic 
factor, vascular endothelial cell growth factor (VEGF) 
[17]. Despite the lack of visible remnants of the 
regressed tumors, if inhibitor treatment was stopped, 
tumors reappeared within two weeks. Although develop- 
ment of resistance is an important unresolved worry, it 
is promising that regrown tumors (two of three), and 
those which doxyrubicin had failed to control (three of 
five) remained sensitive to the inhibitor [16]. 
The mysteries of the mechanism 
Although FTase inhibitors of very different types decrease 
growth of Ras-transformed cells, the specific mechanisms 
of growth inhibition remain unclear. FTase inhibitors 
would not be expected to restore normal function to an 
oncogenic Ras protein, yet tumor cell growth is inhibited 
with little effect on normal cells. It is possible that growth 
inhibition arises from the elimination of farnesylated 
oncogenic Ras, or that cytosolic accumulation of non- 
prenylated oncogenic Ras exerts a dominant negative 
effect [18]. Normal cells would remain unaffected as they 
lack oncogenic Ras. Recent results support the latter 
possibility; treatment of H-Ras-transformed cells with the 
prodrug of FTI-276 caused cytoplasmic accumulation of 
inactive H-Ras/Raf complexes, and blocked oncogenic 
activation of mitogen-activated (MAP) kinase [19], the 
eventual target of Raf. Successful disruption of oncogenic 
signaling by this mechanism would appear to depend 
upon a large amount and slow turnover of the cytosolic 
oncogenic Ras(GTP), which would complex significant 
amounts of Raf (Fig. 1). Conceivably, the rapid hydro- 
lysis of GTP and the release of effecters by normal Ras 
proteins might protect normal cells from this effect. In 
fact, treatment of normal cells with BZA-5B caused 
no change in the EGF-induced activation of MEK and 
MAP kinases [20]. 
On the other hand, FTase inhibitors are not Ras-specific 
and also suppress modification of other farnesylated pro- 
teins [7,11]. The nuclear lamin proteins are clearly farne- 
sylated, and their farnesylation is blocked by inhibitors of 
FTase [21]. Inhibitors also cause dramatic effects on the 
morphology of transformed cells that do not correlate 
temporally with changes in Ras processing, suggesting 
that another farnesylated protein dominates the 
cytoskeletal responses to inhibitor [8]. The RhoB 
protein, which participates in control of the actin 
cytoskeleton, is one possibility, as it has been found to 
contain both C,, and C,, isoprenoids in vim [22]. 
It is in the context of toxicity that the biggest surprises 
have emerged regarding FTase inhibitors. Despite evi- 
dence that inhibitors can enter normal cells and effec- 
tively prevent farnesylation of many proteins, normal 
cells show little change in growth rates. Remarkably, 
inhibitor-treated mice show no apparent ill effects on 
retinal, bone marrow, gastrointestinal tissues or even hair 
follicles [16], tissues that are known to contain farnesyl- 
ated proteins or are dependent upon rapid growth and 
replacement of cells.Thus, in the systems tested so far, in 
which oncogenic Ras proteins have been overexpressed, 
it appears that growth of transformed cells or tumors 
can be inhibited at drug concentrations that leave the 
functions of normal cells intact. 
The next step 
These results point the way to the next important ques- 
tions - what mechanisms are available to normal or 
transformed cells to compensate for the loss of farnesyl- 
ation? Can GGTase I modify Ras proteins, either with its 
standard C,, or perhaps even unconventionally with a 
C,, isoprenoid? GGTase I, at least in vitro, can recognize 
proteins with a variety of residues in the X position and 
can transfer either C,, or C,, isoprenoid [2], with the 
choice depending on incompletely understood attributes 
of the protein substrate [22,23]. K-RasB may well be 
prenylated by GGTase I in vim, as its carboxy-terminal 
polybasic domain and CVIM motif have been shown to 
permit such modification in vitro. A newly developed 
inhibitor (GGTI-287, the carboxy-terminal leucine 
derivative of FTI-276) shows five-fold specificity for 
GGTase I over FTase in vitro, and is more effective at 
blocking K-RasB prenylation and signalling in cells [24]. 
As most human tumors harbor a mutated form of the 
K-Ras gene [l], the participation of GGTase I in the 
prenylation of K-RasB [24], and the resistance of K-RasB 
to inhibition by BZA-2B [23] must be closely studied. 
It is also possible that the loss of Ras farnesylation and 
function may not be as detrimental as we had previously 
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thought. It is already known that the loss of FTase activ- 
ity by genetic knockout is not lethal to yeast [2]. 
Mammalian cells may possess proteins that act as surro- 
gates for Ras when a normal cell’s survival is at stake. 
The closest kin of Ras proteins, the R-Ras and 
R-Ras2/TC21 proteins, which are modified by C,, iso- 
prenoids, could be such substitutes [25]. It is also possi- 
ble that if inhibition of the FTase is incomplete, 
farnesylation and function of small amounts of Ras may 
be sufficient to allow survival of normal cells. 
Finally, some intriguing results suggest that our ignorance 
of cellular isoprenoid metabolism may be greater than we 
had imagined. In recent studies in CHO-Kl cells [21], 
treatment with BZA5B blocked incorporation of farne- 
syl moieties derived from [3H]mevalonate into lamin B 
and prelamin A, and led to accumulation of nuclear 
prelamin A (as prenylation is required for the maturation 
of prelamin A). This treatment, however, had no effect 
upon assembly of the nuclear lamina, even when it was 
continued for 23 days.Why do these proteins continue to 
behave as if they were prenylated? It has been suggested 
[26] that the inhibitor-treated cells might be able to use a 
secondary pathway of isoprenoid metabolism or salvage 
in which isoprenoids not derived directly from 
[3H]mevalonate are attached to proteins. Alternatively, 
these proteins might be modified through an unknown 
farnesylation-independent mechanism that allows matu- 
ration and mnction of proteins that would normally be 
farnesylated [21]. Confirmation of either possibility 
would have a profound impact on further development of 
FTase inhibitors, as both postulate the existence of as yet 
undiscovered enzymes that have been participating in 
protein prenylation.This raises the concern that Ras pro- 
teins may be able to regain tumorigenic activity if such 
alternate pathways become more active during treatment 
with FTase inhibitors. 
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